Johnson & Johnson Surges to 35th in Trading Volume with $2.406 Billion Turnover

On May 30, 2025, Johnson & Johnson (JNJ) saw a significant increase in trading volume, with a turnover of $2.406 billion, marking a 130.39% rise from the previous day. This surge placed JNJ at the 35th position in terms of trading volume for the day. The stock price of JNJ rose by 1.06%, marking the second consecutive day of gains, with a total increase of 1.82% over the past two days.

Johnson & Johnson, a leading healthcare company, is renowned for its expertise in Innovative Medicine and MedTech. The company is dedicated to addressing global health challenges through its innovative solutions. This focus on healthcare innovation positions Johnson & Johnson to prevent, treat, and cure complex diseases, making treatments smarter and less invasive, and providing personalized solutions.

Johnson & Johnson is actively recruiting for a Director, Strategic Business Improvement position in Allschwil, Switzerland. This hybrid role involves leading high-impact strategic projects and continuous improvement initiatives within the Global Medical Safety (GMS) division. The Director will collaborate with various operating units and functions to define and execute strategic actions, ensuring alignment with the overall business strategy. The role requires a minimum of 10 years of experience in pharmacovigilance or related functions, as well as project management and leadership experience. Excellent communication skills and the ability to lead in a matrix organization are essential for this position.